Literature DB >> 12076182

Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Gerardo Gonzalez1, Alison Oliveto, Thomas R Kosten.   

Abstract

New pharmacological treatments for heroin (diamorphine) addiction include drugs that reduce opiate withdrawal symptoms and agents that are given during the maintenance phase of treatment. A variety of different types of pharmacological agents (opioid agonists, partial opioid agonists, opioid antagonists and alpha(2)-adrenoreceptor agonists) are reviewed and the evidence of their use during managed withdrawal and maintenance are presented. Experimental approaches attempting to reduce the time of opiate withdrawal and to accelerate the transition to abstinence are being developed. The combination tablet of buprenorphine and naloxone that is to be introduced for office-based maintenance is currently undergoing intense evaluation in the US. This new approach may facilitate the expansion of treatment while reducing the potential for medication diversion and intravenous use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076182     DOI: 10.2165/00003495-200262090-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  90 in total

1.  Mortality in heroin addiction: impact of methadone treatment.

Authors:  L Grönbladh; L S Ohlund; L M Gunne
Journal:  Acta Psychiatr Scand       Date:  1990-09       Impact factor: 6.392

2.  Recent evolution in opiate dependence in France during generalisation of maintenance treatments.

Authors:  X Thirion; J Micallef; K Barrau; S Djezzar; H Lambert; J L Sanmarco; G Lagier
Journal:  Drug Alcohol Depend       Date:  2001-02-01       Impact factor: 4.492

3.  Naloxone treatment for opiate withdrawal syndrome.

Authors:  N Loimer; R Schmid; O Presslich; K Lenz
Journal:  Br J Psychiatry       Date:  1988-12       Impact factor: 9.319

4.  Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers.

Authors:  E Vining; T R Kosten; H D Kleber
Journal:  Br J Addict       Date:  1988-05

5.  Naltrexone shortened opioid detoxification with buprenorphine.

Authors:  A Umbricht; I D Montoya; D R Hoover; K L Demuth; C T Chiang; K L Preston
Journal:  Drug Alcohol Depend       Date:  1999-10-01       Impact factor: 4.492

6.  Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Authors:  S L Walsh; K L Preston; G E Bigelow; M L Stitzer
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

7.  Clonidine and opiate receptor antagonists in the treatment of heroin addiction.

Authors:  G Gerra; A Marcato; R Caccavari; B Fontanesi; R Delsignore; G Fertonani; P Avanzini; P Rustichelli; M Passeri
Journal:  J Subst Abuse Treat       Date:  1995 Jan-Feb

8.  Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal.

Authors:  S K Lin; J Strang; L W Su; C J Tsai; W H Hu
Journal:  Drug Alcohol Depend       Date:  1997-11-25       Impact factor: 4.492

9.  Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM).

Authors:  F S Tennant; R A Rawson; E Pumphrey; R Seecof
Journal:  J Subst Abuse Treat       Date:  1986

10.  Withdrawal from methadone maintenance. Rate of withdrawal and expectation.

Authors:  E C Senay; W Dorus; F Goldberg; W Thornton
Journal:  Arch Gen Psychiatry       Date:  1977-03
View more
  9 in total

1.  A meta-analysis of Chinese herbal medicine in treatment of managed withdrawal from heroin.

Authors:  Ting-ting Liu; Jie Shi; David H Epstein; Yan-Ping Bao; Lin Lu
Journal:  Cell Mol Neurobiol       Date:  2008-06-27       Impact factor: 5.046

2.  Longitudinal changes of dopamine transporters in heroin users during abstinence.

Authors:  Shasha Xu; Ying Liu; Yu Li; Yangping Deng; Yiyun Huang; Jie Yuan; Rongbin Lv; Yuankai Wang; Guangming Zhang; Zhirui Guo; Mei Han; Xingdang Liu; Daxu Fu
Journal:  Psychopharmacology (Berl)       Date:  2015-06-23       Impact factor: 4.530

Review 3.  Zebrafish: a model for the study of addiction genetics.

Authors:  Eric W Klee; Henning Schneider; Karl J Clark; Margot A Cousin; Jon O Ebbert; W Michael Hooten; Victor M Karpyak; David O Warner; Stephen C Ekker
Journal:  Hum Genet       Date:  2011-12-30       Impact factor: 4.132

4.  Demographic and clinical factors predicting retention in methadone maintenance: results from an Irish cohort.

Authors:  C D Darker; J Ho; G Kelly; L Whiston; J Barry
Journal:  Ir J Med Sci       Date:  2015-05-31       Impact factor: 1.568

5.  Rapid access to morphinones: removal of 4, 5-ether bridge with Pd-catalyzed triflate reduction.

Authors:  Christopher D Hupp; John L Neumeyer
Journal:  Tetrahedron Lett       Date:  2010-04-28       Impact factor: 2.415

Review 6.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

7.  Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment.

Authors:  Ying Liu; Mei Han; Xingdang Liu; Yanping Deng; Yu Li; Jie Yuan; Rongbin Lv; Yuankai Wang; Guangming Zhang; Jinlong Gao
Journal:  Psychopharmacology (Berl)       Date:  2013-05-29       Impact factor: 4.530

Review 8.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

9.  Oleanolic Acid Attenuates Morphine Withdrawal Symptoms in Rodents: Association with Regulation of Dopamine Function.

Authors:  Zhiqi Shi; Shugang Pan; Luolin Wang; Sha Li
Journal:  Drug Des Devel Ther       Date:  2021-08-24       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.